Changes in Renal Function Indices in Chronic Hepatitis C Patients Treated with Sofosbuvir/Daclatasvir, with or without Ribavirin

Abstract

epatitis C infection is a disease with significant global impact, about 130-150 million people chronically infected with HCV, representing about 2-2.5% of the world’s population. In Egypt, the prevalence is 10% and according to the last DHS in 2015 it was 7%. New DAAs drugs have been introduced over the past few years and a combination of two of these drugs; namely sofosbuvir and daclatasvir, are widely used in Egypt nowadays. Our study included 509 patients with chronic HCV infection who received treatment during the last two years in New Cairo viral hepatitis center, one of the NCCVH centers. Four hundred seventy patients were treatment naïve and 39 were treatment experienced. All patients were subjected to full history, clinical examination, laboratory investigations and abdominal ultrasonography. All data of the chronic HCV infection patients who treated with sofosbuvir/daclatasvir, with or without ribavirin with normal baseline creatinine and achieved SVR, were compared and analysed to assess the changes in renal indices during and after HCV treatment.